
- Telehealth Visits
- Insurance plan information

Adnan Alseidi, MD, MBA, M ED
Gastrointestinal Surgical OncologyAssociate Dean of Assessment, Improvement and Accreditation- Telehealth Visits
- Insurance plan information



Adnan Alseidi, MD, MBA, M ED
Gastrointestinal Surgical OncologyAssociate Dean of Assessment, Improvement and Accreditation- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Adnan Alseidi is a surgical oncologist who specializes in conditions involving the liver, bile ducts, pancreas and other parts of the endocrine system. He has particular interests in minimally invasive surgical techniques, spleen preservation techniques, immunology studies and surgery for patients with locally advanced pancreas cancer. He serves as UCSF's associate dean of assessment, improvement and accreditation.
Alseidi's research focuses on surgical education, minimally invasive surgical techniques, and methods to improve outcomes for patients with liver, pancreas and biliary cancers. He has received grants to create registries for minimally invasive pancreas and liver surgeries as part of an international collaboration to support studies leading to better patient outcomes. He specifically studies the use of deep learning networks and other types of artificial intelligence to enhance patient care during surgery and minimize postoperative complications.
Alseidi earned his medical degree from the Pennsylvania State University College of Medicine. He completed a residency in general surgery at the University of Illinois Chicago. He completed a fellowship in hepatobiliary, pancreatic and advanced gastrointestinal surgery at Washington University in St. Louis. He has a master's degree in surgical education from Southern Illinois University and the University of Illinois Urbana-Champaign, as well as a master of business administration degree from Brandeis University.
Alseidi served as a surgeon in the U.S. Navy and as co-director of the surgery department at the U.S. Naval Hospital Okinawa, Japan. During his time in the Navy, he learned the importance of demonstrating principles through his work. He believes in respecting others unconditionally and that giving oneself over to serving others is the ultimate honor.
Before coming to UCSF, Alseidi was a hepatobiliary and endocrine surgeon at Virginia Mason Medical Center. He also served as associate director of its general surgery residency program, directed its hepatobiliary clinical fellowship, and directed surgical simulation training at the facility.
Alseidi is a former president of both the Association for Surgical Education and the Fellowship Council. He is chair for hepatobiliary surgery in the Society of American Gastrointestinal and Endoscopic Surgeons and chair of education and training for both the Americas Hepato-Pancreato-Biliary Association and the International Laparoscopic Liver Society. He is an active committee member for the American College of Surgeons.
Education & training
Board certification
- General Surgery, American Board of Surgery
Fellowship
- Hepa-Pancreato-Biliary Adv GI Surgery, Washington University School of Medicine
Residency
- General Surgery, University of Illinois at Chicago College of Med
Internship
- General Surgery, York Hospital GME
Degree
- MD, Pennsylvania State University of Medicine
My expertise
Specialties
Conditions
- Pancreatic Cancer
- Liver Cancer
- Bile Duct Mass
- Gallbladder Cancer
Locations
My work

Tackling cancer with the Whipple procedure
Clinical Trials query: q=health_gateway_id_ss%3A%28%223586%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%223586%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.